Compare Sanofi SA (SNY) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs TotalEnergies SE — how do they compare? Sanofi SA trades at $43.62 (market cap $104.30B), while TotalEnergies SE trades at $87.48 (market cap $196.06B). The key difference: TotalEnergies SE is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| SNY | TTE | |
|---|---|---|
Market Cap | $104.30B | $196.06B |
Sector | Health | Energy |
52-Week High | $52.34 | $93.60 |
52-Week Low | $41.33 | $57.39 |
Enterprise Value | $124.19B | $227.06B |
Dividend Yield | 5.55% | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
TotalEnergies (TTE) trades at $87.49, down 0.53% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $94.00. The company reported mixed recent earnings, missing in Q4 2025 but beating in Q1 and Q2 2026, while revenue has declined from $263.3B in 2022 to $182.3B in 2025. Recent strategic moves include acquiring Shell's European onshore renewables business and developing the Cronos gas field in Cyprus, signaling a shift toward integrated energy.
TTE presents a value opportunity with a low P/E of 11.01 and strong cash flow, but faces headwinds from declining revenue and regulatory climate litigation. The stock's upside is supported by analyst bullishness and dividend payments, yet investors must weigh energy transition execution risks against its current attractive valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
